✦ LIBER ✦

Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in Myeloma

✍ Scribed by Richardson, P.

Book ID: 121855014
Publisher: American Society of Clinical Oncology
Year: 2004
Tongue: English
Weight: 134 KB
Volume: 22
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2004.05.984

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Apoptotic signaling induced by immunomod

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

✍ Mitsiades, N. 📂 Article 📅 2002 🏛 American Society of Hematology 🌐 English ⚖ 149 KB

Rates of venous thromboembolism in multi

Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis

✍ M. CARRIER; G. LE GAL; J. TAY; C. WU; A. Y. LEE 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB

Atypical serum immunofixation patterns f

Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma

✍ Tomer Mark; David Jayabalan; Morton Coleman; Roger N. Pearse; Y. Lynn Wang; Rich 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 290 KB

Genetic and Molecular Epidemiology of Mu

Genetic and Molecular Epidemiology of Multiple Myeloma || Cap-Dependent Protein Translation Initiation in Multiple Myeloma: An Attractive Target for Therapy

✍ Lentzsch, Suzanne 📂 Article 📅 2012 🏛 Springer New York 🌐 English ⚖ 474 KB

Multiple myeloma is a plasma cell malignancy characterized by complex heterogenous cytogenetic abnormalities that accounts for 1.4% of all cancers, and approximately 10% of hematologic malignancies. The clinical manifestations of multiple myeloma include lytic bone lesions, cytopenia, hypercalcemia,